X0306 4 2022-06-24 0 0001642380 Oncocyte Corp OCX 0001590144 PURA VIDA INVESTMENTS, LLC 512 W 22ND STREET 7TH FLOOR NEW YORK NY 10011 0 0 1 0 0001789193 Kamen Efrem C/O PURA VIDA INVESTMENTS, LLC 512 W 22ND STREET, 7TH FLOOR NEW YORK NY 10011 0 0 1 0 Common Stock 2022-06-24 4 S 0 10964 1.0514 D 7462643 I By Pura Vida Master Fund, Ltd. Common Stock 2022-06-24 4 S 0 35441 1.0269 D 7427202 I By Pura Vida Master Fund, Ltd. Common Stock 2022-06-24 4 S 0 12517 1.0514 D 8520146 I By the Managed Accounts. Common Stock 2022-06-24 4 S 0 40464 1.0269 D 8479682 I By the Managed Accounts. Aggregate number of shares sold on the same date at difference prices. Represents the weighted-average sales price. The shares were sold in multiple transactions at prices ranging from $1.04 to $1.09, inclusive, per share. Full information regarding the number of shares sold at each price shall be provided to the Securities and Exchange Commission staff (the "Staff), Issuer or any security holder, upon request. Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund") and certain separately managed accounts (the "Managed Accounts," and together with the Pura Vida Master Fund, collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any. Represents the weighted-average sales price. The shares were sold in multiple transactions at prices ranging from $1.02 to $1.0475, inclusive, per share. Full information regarding the number of shares sold at each price shall be provided to the Staff, Issuer or any security holder, upon request. Although these sales are matchable transactions to purchases on April 14, 2022 under Section 16(b) of the Securities Exchange Act of 1934, as amended, the sales prices are less than the purchase prices, constituting a loss and, as such, there are no profits to disgorge pursuant to Section 16(b). /s/ Efrem Kamen, Managing Member of Pura Vida Investments, LLC 2022-06-28 /s/ Efrem Kamen 2022-06-28